The Finecure Legacy: 20 Years of Pharmaceutical & Manufacturing Excellence

Incorporated in 2005 and headquartered in Ahmedabad, Finecure Pharmaceuticals Limited manufactures finished dosage formulations at a scale of over 4,000 million tablets and 3,000 million capsules a year. Two decades on from our beginnings as a specialised formulation unit, we operate four WHO-GMP sites, a portfolio of 254 commercialised formulations and a 1,000-strong team, guided throughout by a single mission: making lives healthier.

Production runs across Gujarat and Uttarakhand, spanning seven therapeutic verticals in pharmaceuticals, nutraceuticals and OTC. Development runs through our DSIR-recognised R&D centre, covering generics, complex generics and novel drug delivery systems, with technology transfer to commercial scale handled in-house.

Two commercial channels operate from one quality system. In India, our branded prescription division reaches 40,000+ medical practitioners and 80,000+ pharmacies.

Internationally, we supply 20+ markets across South East Asia, Africa, WANA, Latin America and North America, backed by 100+ product registrations and destination-specific CTD, eCTD and ACTD dossiers. For our international partners, registration is the starting point. Submissions are prepared to match each authority's requirements, with WHO-GMP certificates and Certificates of Pharmaceutical Product issued from our certified sites. Our regulatory team tracks USP, BP and EP revisions so submission packages remain current. Product is available under your own brand, as private label, or under Finecure brands. Manufacturing is organised around dedicated sites. Our general oral solid dosage site has been successfully USFDA audited, with an Establishment Inspection Report issued. Our Amoxicillin-Clavulanate site is built as a 100% physically isolated block with fully dedicated production lines, allowing beta-lactam and non-beta-lactam production to run in parallel with no cross-contamination risk. High-speed automated lines carry GS1-compliant serialisation across the portfolio.

Finecure has been named Best Healthcare Brand by The Economic Times twice, in 2023 and again in 2026, and received the Zee Architects of Viksit Bharat Award in 2026. Earlier recognitions include The Entrepreneur Award from Entrepreneur Magazine and the UBM Award.